Search
Moricizine
go.drugbank.com/drugs/DB00680ApprovedWithdrawnAn antiarrhythmia agent used primarily for ventricular rhythm disturbances.
Attapulgite
go.drugbank.com/drugs/DB01574ApprovedVet approvedWithdrawnFor that reason, it has often been used in antidiarrheal medications. Until 2003, it was the active ingredient used in Kaopectate, before that product was reformulated with bismuth subsalicylate.
Categories: Compounds used in a research, industrial, or household settingCryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects. Cryptenamine has a m...
Categories: Heterocyclic Compounds with 4 or More RingsBiguanide
go.drugbank.com/drugs/DB13100ApprovedInvestigationalWithdrawnBiguanide has been investigated for the treatment of Diabetes Mellitus.
Metocurine iodide
go.drugbank.com/drugs/DB00416ApprovedWithdrawnMetocurine Iodide is no longer available on the US market.
Carbamoylcholine
go.drugbank.com/drugs/DB00411Approved[A226315] Carbamoylcholine was initially used as a treatment for migraines,[A226365] induction of diuresis,[A226370] and other parasympathetic effects.
Categories: Compounds used in a research, industrial, or household settingMotexafin lutetium
go.drugbank.com/drugs/DB05296InvestigationalMotexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin.
Categories: Heterocyclic Compounds with 4 or More RingsImexon
go.drugbank.com/drugs/DB05003InvestigationalImexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives.
Thymalfasin
go.drugbank.com/drugs/DB04900InvestigationalThymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases.
Capivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigational[A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or … Therefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor.